Let’s take a brief check on where covering Street analysts see Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) moving in the near-term. Analysts taken into consideration by Thomson Reuters have a current consensus target on company shares of $22.50. It is useful to remember that target price projections can greatly vary from analyst to analyst. Covering analysts use their deep knowledge and expertise to help create their best calculation of where they think shares could be moving in the future.
After a look at recent stock performance, shares have traded $0.67 off of the 50-day moving average of $16.08 and $3.25 off of the 200-day moving average of $13.50. Shares have been recorded at -6.94% separated from the 52-week high of 18.00 and +142.41% away from the 52-week low of 6.91. Tracking the stock price in relation to moving averages as well as highs and lows for the year might assist with evaluating future stock performance.
Street analysts have the ability to employ multiple metrics to help calculate target price estimates. A common metric is a company’s P/E Ratio. This calculation is derived by dividing the current share price by the projected earnings per share. Vanda Pharmaceuticals Inc. presently has a P/E Ratio of N/A. Investors may also monitor a company’s PEG or price to earnings growth ratio. The PEG ratio represents the ratio of the price to earnings to the anticipated future growth rate of the company. A PEG Ratio under one may indicate that the company is undervalued. If a company has a PEG Ratio above one, it may represent that the company is overvalued. A PEG Ratio near one might be seen as fair value. The company has a current PEG Ratio of 0.00.